Antiviral Drugs Market by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others), Type (Branded and Generic), Application (HIV, Hepatitis, Herpes, Influenza, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global antiviral drugs market size was valued at USD 56.4 billion in 2019 and is projected to expand during the forecast period, 2021–2028. The growth of the market is attributed to the increasing geriatric population and increasing demand for efficient treatment of human immunodeficiency virus (HIV) infections.
Antiviral drugs are prescription medicines (pills, liquid, inhaled powder, or intravenous solution) that combat flu viruses in your body. Antiviral drugs are not available over-the-counter. They can only be obtained with a prescription from a medical professional. Antiviral drugs are not the same as antibiotics, which are used to treat bacterial infections. The majority of antiviral drugs now in the market are intended to treat HIV, herpes viruses, SARS-CoV-2, hepatitis B and C viruses, and influenza A and B viruses. Antivirals are being developed for various disease families, according to researchers. viruses reproduce in the host's cells, therefore it's tough to create safe and efficient antiviral drugs. This makes it challenging to develop drug targets that will interfere with the virus without damaging the cells of the host organism. Furthermore, viral diversity is a key hindrance in the development of vaccines and antiviral drugs. Patients who are at a higher risk of developing complications, have a severe illness, or are experiencing worsening symptoms should get treatment as soon as possible.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of diseases such as human immunodeficiency virus (HIV), hepatitis, and influenza are projected to drive the market growth during the forecast year.
- Increasing geriatric population worldwide is anticipated to boost the market growth during the forecast period.
- Increasing advancements in epidemiology and increased awareness of viral diseases among people around the world are the factors boosting the market growth during the forecast period.
- High cost of drug development is projected to restrict the market growth.
- Increasing preventative measures for various diseases are anticipated to impede the market growth during the forecast period.
- Increasing demand for alternative treatments such as naturopathy and homeopathy are anticipated to hamper the market growth in the forecast period.
- Increasing emphasis on R&D for the development of new treatments, medicine, and technology such as vaccines and combination therapies are expected to offer lucrative opportunities for the market players.
Scope of the Report
The report on the global antiviral drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Antiviral drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others), Type (Branded and Generic), Application (HIV, Hepatitis, Herpes, Influenza, and Others) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Bristol-Myers Squibb Company; Cipla Inc.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd. |
Market Segment Insights
Reverse transcriptase inhibitors segment is expected to account for a key share of the market
Based on drug class, the antiviral drugs market is segmented into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others. The reverse transcriptase inhibitors segment is expected to account for a key share of the market during the forecast period owing to its effectiveness in preventing the viral infection or slowing it down. Nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors are two types of reverse transcriptase inhibitors (NNRTIs). Zidovudine, Stavudine, Zalcitabine, Efavirenz, Nevirapine, Etravirine, and Didanosine are some of the drugs used to treat HIV.
Branded segment is expected to constitute a key share of the market
Based on type, the antiviral drugs market is bifurcated into branded and generic. The branded segment is expected to constitute a key share of the market during the forecast period due to it is being associated as safer and effective medication compared to generic medication.
On the other hand, the generic segment is anticipated to expand at a rapid pace during the forecast period owing to its increasing application in developing countries and expiry of patent of some branded products. Furthermore, a number of companies, including Cipla Inc., Aurobindo Pharma, and Dr. Reddy's Laboratories Ltd., focus on producing generic medications at lower prices.
Hepatitis segment is expected to represent a key share of the market
Based on application, the antiviral drugs market is segmented into HIV, hepatitis, herpes, influenza, and others. The hepatitis segment is expected to represent a key share of the market during the forecast period owing to availability of various antiviral drugs such as entecavir, tenofovir, lamivudine, telbivudine, and adefovir. Antiviral medicine demand is projected to rise as the number of cases of hepatitis increases.
On the other hand, the HIV segment is anticipated to expand at a rapid pace during the forecast period due to rising incidence of HIV and, in certain cases, the resulting development of AIDS, as well as the development of a strong pipeline of antiviral medications for HIV therapy.
North America is anticipated to dominate the market
On the basis of regions, the antiviral drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to presence of key players in the region, the availability of advanced healthcare infrastructure, and increasing awareness.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing patient population, improved economic stability, and the presence of a large and established generic medication industry.
Segments
Segments Covered in the ReportThe global antiviral drugs market has been segmented on the basis of
Drug Class
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Neuraminidase Inhibitors
- Others
- Branded
- Generic
- HIV
- Hepatitis
- Herpes
- Influenza
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Gilead Sciences
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- AbbVie
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Cipla Inc.
- Aurobindo Pharma
- Dr. Reddy’s Laboratories Ltd.
Competitive Landscape
Key players competing in the antiviral drugs market are Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Bristol-Myers Squibb Company; Cipla Inc.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd.
Some of the key business strategies employed by the companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
For example, in May 2020, Cipla and Gilead Sciences formed a strategic collaboration to develop and market an investigational medicine for the treatment of COVID-19 patients.
For example, in June 2019, Cidara Therapeutics Inc., a biotechnology firm focusing on developing innovative anti-infectives, released new findings from trials of CB-012, its Cloudbreak antiviral Fc-conjugate (AVC) candidate for influenza. In the forecast period, the innovative product launches from this strong pipeline are expected to boost market growth.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Antiviral Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Antiviral Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Antiviral Drugs Market - Supply Chain
4.5. Global Antiviral Drugs Market Forecast
4.5.1. Antiviral Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Antiviral Drugs Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Antiviral Drugs Market Absolute $ Opportunity
5. Global Antiviral Drugs Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Antiviral Drugs Market Size and Volume Forecast by Types
5.3.1. Branded
5.3.2. Generic
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Antiviral Drugs Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Antiviral Drugs Market Size and Volume Forecast by Applications
6.3.1. HIV
6.3.2. Hepatitis
6.3.3. Herpes
6.3.4. Influenza
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Antiviral Drugs Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Antiviral Drugs Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Antiviral Drugs Demand Share Forecast, 2019-2026
8. North America Antiviral Drugs Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Antiviral Drugs Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Antiviral Drugs Market Size and Volume Forecast by Types
8.4.1. Branded
8.4.2. Generic
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Antiviral Drugs Market Size and Volume Forecast by Applications
8.7.1. HIV
8.7.2. Hepatitis
8.7.3. Herpes
8.7.4. Influenza
8.7.5. Others
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Antiviral Drugs Demand Share Forecast, 2019-2026
9. Latin America Antiviral Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Antiviral Drugs Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Antiviral Drugs Market Size and Volume Forecast by Types
9.4.1. Branded
9.4.2. Generic
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Antiviral Drugs Market Size and Volume Forecast by Applications
9.7.1. HIV
9.7.2. Hepatitis
9.7.3. Herpes
9.7.4. Influenza
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Antiviral Drugs Demand Share Forecast, 2019-2026
10. Europe Antiviral Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Antiviral Drugs Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Antiviral Drugs Market Size and Volume Forecast by Types
10.4.1. Branded
10.4.2. Generic
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Antiviral Drugs Market Size and Volume Forecast by Applications
10.7.1. HIV
10.7.2. Hepatitis
10.7.3. Herpes
10.7.4. Influenza
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Antiviral Drugs Demand Share Forecast, 2019-2026
11. Asia Pacific Antiviral Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Antiviral Drugs Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Antiviral Drugs Market Size and Volume Forecast by Types
11.4.1. Branded
11.4.2. Generic
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Antiviral Drugs Market Size and Volume Forecast by Applications
11.7.1. HIV
11.7.2. Hepatitis
11.7.3. Herpes
11.7.4. Influenza
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Antiviral Drugs Demand Share Forecast, 2019-2026
12. Middle East & Africa Antiviral Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Antiviral Drugs Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Antiviral Drugs Market Size and Volume Forecast by Types
12.4.1. Branded
12.4.2. Generic
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Antiviral Drugs Market Size and Volume Forecast by Applications
12.7.1. HIV
12.7.2. Hepatitis
12.7.3. Herpes
12.7.4. Influenza
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Antiviral Drugs Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Antiviral Drugs Market: Market Share Analysis
13.2. Antiviral Drugs Distributors and Customers
13.3. Antiviral Drugs Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Gilead Sciences
13.4.2. F. Hoffmann-La Roche AG
13.4.3. GlaxoSmithKline plc
13.4.4. AbbVie
13.4.5. Merck & Co., Inc.
13.4.6. Johnson & Johnson Services, Inc.
13.4.7. Bristol-Myers Squibb Company
13.4.8. Cipla Inc
2. Assumptions and Acronyms Used
3. Research Methodology
4. Antiviral Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Antiviral Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Antiviral Drugs Market - Supply Chain
4.5. Global Antiviral Drugs Market Forecast
4.5.1. Antiviral Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Antiviral Drugs Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Antiviral Drugs Market Absolute $ Opportunity
5. Global Antiviral Drugs Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Antiviral Drugs Market Size and Volume Forecast by Types
5.3.1. Branded
5.3.2. Generic
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Antiviral Drugs Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Antiviral Drugs Market Size and Volume Forecast by Applications
6.3.1. HIV
6.3.2. Hepatitis
6.3.3. Herpes
6.3.4. Influenza
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Antiviral Drugs Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Antiviral Drugs Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Antiviral Drugs Demand Share Forecast, 2019-2026
8. North America Antiviral Drugs Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Antiviral Drugs Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Antiviral Drugs Market Size and Volume Forecast by Types
8.4.1. Branded
8.4.2. Generic
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Antiviral Drugs Market Size and Volume Forecast by Applications
8.7.1. HIV
8.7.2. Hepatitis
8.7.3. Herpes
8.7.4. Influenza
8.7.5. Others
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Antiviral Drugs Demand Share Forecast, 2019-2026
9. Latin America Antiviral Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Antiviral Drugs Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Antiviral Drugs Market Size and Volume Forecast by Types
9.4.1. Branded
9.4.2. Generic
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Antiviral Drugs Market Size and Volume Forecast by Applications
9.7.1. HIV
9.7.2. Hepatitis
9.7.3. Herpes
9.7.4. Influenza
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Antiviral Drugs Demand Share Forecast, 2019-2026
10. Europe Antiviral Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Antiviral Drugs Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Antiviral Drugs Market Size and Volume Forecast by Types
10.4.1. Branded
10.4.2. Generic
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Antiviral Drugs Market Size and Volume Forecast by Applications
10.7.1. HIV
10.7.2. Hepatitis
10.7.3. Herpes
10.7.4. Influenza
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Antiviral Drugs Demand Share Forecast, 2019-2026
11. Asia Pacific Antiviral Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Antiviral Drugs Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Antiviral Drugs Market Size and Volume Forecast by Types
11.4.1. Branded
11.4.2. Generic
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Antiviral Drugs Market Size and Volume Forecast by Applications
11.7.1. HIV
11.7.2. Hepatitis
11.7.3. Herpes
11.7.4. Influenza
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Antiviral Drugs Demand Share Forecast, 2019-2026
12. Middle East & Africa Antiviral Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Antiviral Drugs Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Antiviral Drugs Market Size and Volume Forecast by Types
12.4.1. Branded
12.4.2. Generic
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Antiviral Drugs Market Size and Volume Forecast by Applications
12.7.1. HIV
12.7.2. Hepatitis
12.7.3. Herpes
12.7.4. Influenza
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Antiviral Drugs Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Antiviral Drugs Market: Market Share Analysis
13.2. Antiviral Drugs Distributors and Customers
13.3. Antiviral Drugs Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Gilead Sciences
13.4.2. F. Hoffmann-La Roche AG
13.4.3. GlaxoSmithKline plc
13.4.4. AbbVie
13.4.5. Merck & Co., Inc.
13.4.6. Johnson & Johnson Services, Inc.
13.4.7. Bristol-Myers Squibb Company
13.4.8. Cipla Inc
Segments Covered in the Report
The global antiviral drugs market has been segmented on the basis of
Drug Class
The global antiviral drugs market has been segmented on the basis of
Drug Class
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Neuraminidase Inhibitors
- Others
- Branded
- Generic
- HIV
- Hepatitis
- Herpes
- Influenza
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Gilead Sciences
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- AbbVie
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Cipla Inc.
- Aurobindo Pharma
- Dr. Reddy’s Laboratories Ltd.
Key players competing in the antiviral drugs market are Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Bristol-Myers Squibb Company; Cipla Inc.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd.
Some of the key business strategies employed by the companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
For example, in May 2020, Cipla and Gilead Sciences formed a strategic collaboration to develop and market an investigational medicine for the treatment of COVID-19 patients.
For example, in June 2019, Cidara Therapeutics Inc., a biotechnology firm focusing on developing innovative anti-infectives, released new findings from trials of CB-012, its Cloudbreak antiviral Fc-conjugate (AVC) candidate for influenza. In the forecast period, the innovative product launches from this strong pipeline are expected to boost market growth.
Our Clients
Related Reports
Some other reports from this category!
